Shares of Biohaven Pharma Hldgs BHVN rose 0.8% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share decreased 2.75% year over year to ($2.62), which beat the estimate of ($2.74).
Revenue of $92,933,000 higher by 858.27% from the same period last year, which beat the estimate of $78,130,000.
Outlook
Earnings guidance hasn't been issued by the company for now.
Biohaven Pharma Hldgs hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: Aug 09, 2021
Time: 08:30 AM
ET Webcast URL: https://event.webcasts.com/starthere.jsp?ei=1475570&tp_key=e778be1236
Technicals
Company's 52-week high was at $132.91
52-week low: $57.66
Price action over last quarter: Up 78.09%
Company Description
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
